All In Biotech

Drug Trial Radar · NCT02582736

Antipsychotics and Risk of Hyperglycemic Emergencies

Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data

Last checked: Nov 19, 2026Latest source record: Oct 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

725,489

Actual

Start

Apr 2012

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Drug Safety and Effectiveness Network, Canada; Canadian Institutes of Health Research (CIHR)
First posted
Oct 21, 2015

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.

Conditions

  • Psychotic Disorders
  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Diabetes Mellitus, Type 2

Interventions

  • OlanzapineDrug

    Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.

  • RisperidoneDrug

    Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.

  • atypical antipsychotics (other)Drug

    Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.

  • typical antipsychoticsDrug

    Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospitalization for a hyperglycemic emergencyTime frame: Patients will be followed from the date of study cohort entry until the occurrence of a hyperglycemic emergency, censoring, or for up to 365 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Women's College Hospital, Women's College Research Institute

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.